Abu Dhabi - Mubasher: Burjeel Holdings achieved net profits worth AED 186.86 million during the first half (H1) of 2025, reflecting an annual increase from AED 168.87 million.

Revenues rose to AED 2.67 billion in the first six months (6M) of 2025 from AED 2.38 billion in H1-24, the financial results showed.

Basic and diluted earnings per share (EPS) stood at AED 0.04 in H1-25, against AED 0.03 in the same period last year.

Financials for Q2-25

In the second quarter (Q2) of 2025, Burjeel Holdings posted higher net profits at AED 147.66 million, compared to AED 64.41 million in Q2-24.

The revenues surged by 18.70% to AED 1.40 billion in Q2-25 from AED 1.18 billion in April-June 2024, while the basic and diluted EPS grew to AED 0.03 from AED 0.01.

John Sunil, CEO of Burjeel Holdings, stated: “These results reflect tangible progress in key operational areas such as physician manpower optimization, formulary management, and cost control, while our strategic focus on superspecialty care is beginning to yield measurable benefits, enhancing both revenue and profitability.”

“We also advanced key strategic priorities, reinforcing leadership in complex care across oncology, transplants, fertility, mental health, and diagnostics,” the CEO added.

He concluded: “Our focus remains on converting recent investments into sustained expansion and margin improvement, while maintaining disciplined financial management to support long-term shareholder value.”

In Q1-25, Burjeel Holdings registered net profits attributable to the shareholders of AED 36.37 million, an annual drop from AED 102.01 million.

Last May, the ADX-listed group’s board decided to distribute cash dividends amounting to AED 170 million, representing 47% of the company’s net profit, for 2024.